Accueil   Diary - News   All news Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

Saint-Herblain (France), December 17, 2018 – Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.

 

 

The overall Phase 2 objective for VLA15 is to determine the optimal dosage level and schedule for use in Phase 3 pivotal field efficacy studies, based on immunogenicity and safety data.

 


The Phase 2 development for the Lyme disease vaccine candidate will include the evaluation of the highest dose of VLA15 tested in Phase 1 in addition to two higher doses. Furthermore, the company plans to include the evaluation of an additional, alternative three-dose schedule.

 

 

 

Read the press release